Summary: In this issue of Cancer Discovery, Suehnholz and colleagues describe their efforts to quantify the gradual yet steady progress of precision oncology by surveying the regulatory approvals of targeted cancer therapies, and thus the actionability of corresponding molecular alterations in clinical practice, over more than 20 years. Their work also suggests a relationship between the discovery of candidate therapeutic targets through comprehensive tumor profiling and molecularly guided cancer drug development. See related article by Suehnholz et al., p. 49 (5).

中文翻译：

---

衡量精准肿瘤学的进展

摘要：在本期《癌症发现》中，Suehnholz 及其同事描述了他们通过调查靶向癌症治疗的监管批准以及临床实践中相应分子改变的可操作性来量化精准肿瘤学的逐步而稳定的进展所做的努力，超过20年。他们的工作还表明，通过全面的肿瘤分析发现候选治疗靶点与分子引导的癌症药物开发之间存在联系。请参阅 Suehnholz 等人的相关文章，第 17 页。49（5）。